Cargando…

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center

CONTEXT: Patients with solid tumors or hematologic malignancies could have severe COVID-19 outcomes. Patients diagnosed with these types of oncological diseases presented risk factors for severe forms of COVID-19: obesity, arterial hypertension, thrombosis, and diabetes mellitus. OBJECTIVE: The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popov, Viola Maria, Iliescu, Lelia, Pirvu, Catalina, Grigorie, Andra, Constantin, Oana, Rus, Ana, Badoiu, Dana Mihaela Niculae, Badea, Adriana, Omer, Meilin, Andreescu, Mihaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Acute Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404068/ http://dx.doi.org/10.1016/S2152-2650(21)01685-2

Ejemplares similares

Poster: AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Early response evaluation in AML using mass cytometry
por: Gjertsen, Bjørn T., et al.
Publicado: (2019)

P1602: THE ASSESSMENT OF LYMPHOPENIA AS RISK FACTOR FOR UNFAVORABLE EVOLUTION OF PATIENTS WITH SEVERE FORM OF COVID 19
por: Popov, V., et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy
por: Ihlow, Jana, et al.
Publicado: (2021)

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
por: Arruda, Lucas C. M., et al.
Publicado: (2022)

A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
por: Xu, Xi, et al.
Publicado: (2022)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc
por: Garcia-Cuellar, Maria-Paz, et al.
Publicado: (2022)

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia
por: Tuval, Amos, et al.
Publicado: (2022)

Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
por: Li, Xue, et al.
Publicado: (2022)

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers
por: Wu, Shishuang, et al.
Publicado: (2022)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia
por: Sourdeau, Elise, et al.
Publicado: (2022)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

Analysis of rare driving events in pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Pabst, Thomas, et al.
Publicado: (2023)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
por: Sahoo, Binay K., et al.
Publicado: (2022)

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlsep5etank3lqviecu3hn6j7u